-
Bank Ranking
Banks Ratios
Cement Statistics
Cement Ranking
Cement Ratios
Monetary and Economic Statistics
Oil, Gas and Fuel
Macro Economy
Consumer Spending
Inflation
Exports & Imports
Food Prices
Non Food Prices
Construction Materials
Petrochem. Ranking
Petrochem. Ratios
Retail Rankings
Retail Ratios
Grocery Ranking
Grocery Ratios
Top Growth
Dividend History
Almujtama Alraida net profit plummets 30% to SAR 7.9M in 2024, H2 at SAR5.9M
Almujtama Alraida Medical Co. reported a net profit of SAR 7.9 million for 2023, a 30% slump from SAR 11.4 million a year earlier.
Financials (M)
| Item | 2023 | 2024 | Change |
|---|---|---|---|
| Revenues | 407.74 | 430.75 | 5.6 % |
| Gross Income | 129.21 | 142.12 | 10.0 % |
| Operating Income | 13.95 | 7.74 | (44.5 %) |
| Net Income | 11.39 | 7.93 | (30.4 %) |
| Average Shares | 9.50 | 9.50 | - |
| Earnings Per Share before unusual items | 1.20 | 0.83 | (30.4 %) |
| EPS (Riyals) | 1.20 | 0.83 | (30.4 %) |
The company attributed the year-on-year (YoY) profit decline to an increase in operating expenses by SAR 20 million, due to increased investments, including new store openings across the Kingdom.
Almujtama Alraida also reported a depreciation expense, which commenced in 2024, of the main warehouse in the Saudi Authority for Industrial Cities (MODON). Moreover, there was an increase of SAR 2 million compared to the previous year, primarily comprising interest expenses related to lease contract obligations, to support sales growth. This was offset by a 5.6% YoY increase in revenues in 2024. The growth resulted in an increase of SAR 22.8 million, bringing total sales to SAR 430.8 million, compared to SAR 407.7 million in 2023. This was primarily attributed to the expansion of its pharmacy network and its commitment to providing competitive value to its customers.
Current Quarter Comparison (M)
| Item | Q4 2023 | Q4 2024 | Change |
|---|---|---|---|
| Revenues | 203.61 | 221.36 | 8.7 % |
| Gross Income | 62.52 | 73.27 | 17.2 % |
| Operating Income | 0.79 | 4.12 | 423.5 % |
| Net Income | 0.06 | 5.95 | 9729.1 % |
| Average Shares | 9.50 | 9.50 | - |
| Earnings Per Share before unusual items | 0.01 | 0.63 | 9729.1 % |
| EPS (Riyals) | 0.01 | 0.63 | 9729.1 % |
Net profit leapt 200.2% to SAR 5.95 million in H2 2024 from SAR 1.98 million in H1 2024.
Total shareholders’ equity, no minority interest, rose to SAR 138.14 million by Dec. 31, 2024, from SAR 129.78 million a year ago.
View other reports
Share Price
Almujtama Alraida Medical Co. (ALMUJTAMA MEDICAL)
| Current | |
| Market Cap (M Riyal) | 289.28 |
| Enterprise Value (EV) (M) | 287.10 |
| Shares Outstanding ((M)) | 9.50 |
| Book Value (BV) ( Riyal) | 14.54 |
| Par Value ( Riyal) | 10.00 |
| Adjusted P/E (Last12) | 36.49 |
| Price/book | 2.09 |
Financial results (Million)
| Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
|---|---|---|---|---|---|---|
| Q1 2024 | - | - | - | - | - | - |
| Q2 2024 | 209.40 | 2.6 % | 68.86 | 3.3 % | 3.62 | (72.5 %) |
| Q3 2024 | - | - | - | - | - | - |
| Q4 2024 | 221.36 | 8.7 % | 73.27 | 17.2 % | 4.12 | 423.5 % |
| 2024 | 430.75 | 5.6 % | 142.12 | 10.0 % | 7.74 | (44.5 %) |
Profit Performance (Million)
| Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | Earnings Per Share before unusual items |
|---|---|---|---|---|---|---|
| Q1 2024 | - | - | - | - | - | - |
| Q2 2024 | 1.98 | (82.5 %) | 0.21 | - | 1.98 | 0.21 |
| Q3 2024 | - | - | - | - | - | - |
| Q4 2024 | 5.95 | 9729.1 % | 0.63 | - | 5.95 | 0.63 |
| 2024 | 7.93 | (30.4 %) | 0.83 | - | 7.93 | 0.83 |
Profitability
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2024 | - | - | - |
| Q2 2024 | 31.81 % | 9.62 % | 0.49 % |
| Q3 2024 | - | - | - |
| Q4 2024 | 32.99 % | - | 1.84 % |
| 2024 | 32.99 % | 11.37 % | 1.84 % |
Per Share Data (Riyal)
| Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| Q1 2024 | - | - | - | - |
| Q2 2024 | 9.50 | 0.21 | 0.21 | 13.87 |
| Q3 2024 | - | - | - | - |
| Q4 2024 | 9.50 | 0.83 | 0.83 | 14.54 |
Multiple Ratios (End of Period Price)
| Period | P/E | Adjusted P/E | Price/book |
|---|---|---|---|
| Q1 2024 | - | - | - |
| Q2 2024 | More than 100 | More than 100 | 2.23 |
| Q3 2024 | - | - | - |
| Q4 2024 | 36.97 | 36.97 | 2.12 |
Business Segments (Million)
Q2 2023
| Period | Pharmaceutical products | Personal care products | Mother and baby care products | Nutritional supplements | Medical tools and devices |
|---|---|---|---|---|---|
| Q2 2023 | 130.28 | 35.29 | 19.22 | 14.45 | 4.89 |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}